# CT-G32: Celltrion's Quadruple Agonist Obesity Drug Explained

Source: https://www.dietglp.com/blog/ct-g32/
Published: 2026-11-04
Keywords: ct-g32, ct g32, celltrion ct-g32, 셀트리온 ct-g32, sco-940, celltrion obesity drug, quadruple agonist glp, quadruple agonist glp 1, quadruple agonist weight loss, quadruple agonist weight loss drug, new quadruple agonist, quadruple receptor agonist, quadruple agonist peptide, quadruple agonist glp name

**TL;DR:** CT-G32, also called SCO-940, is an experimental weekly-shot candidate from Korea's Celltrion and Japan's SCOHIA that acts on four hormone receptors at once: GLP-1, GIP, glucagon and amylin. On November 4, 2026, Celltrion said that in obese rodents it caused more weight loss than retatrutide at the same dose, with a smaller share of lean mass lost, but it has not been tested in a single human yet. Celltrion plans to ask the FDA to start trials by February 2027, so it is many years from pharmacies. On the GLP-1 you take today, [Sharpy](https://apps.apple.com/us/app/glp-diet-app-sharpy/id6762084138) helps you protect muscle with one protein target, one 20-minute workout and one Shape Score a day.

What is CT-G32, the new "quadruple agonist" from Celltrion? **CT-G32 is an experimental obesity drug candidate that acts on four hormone receptors with one molecule: GLP-1, GIP, glucagon and amylin.** Korea's Celltrion is developing it with Japan's SCOHIA, which calls it SCO-940. On November 4, 2026, Celltrion said that in obese rodents it caused more weight loss than Eli Lilly's retatrutide at the same dose. It has not been tested in people yet, and human trials may start in 2027.

Celltrion shared the data at the TIDES Europe conference in Amsterdam, which runs November 3 to 5, 2026. Korean outlets, including the Seoul Economic Daily and Korea Biomedical Review, reported it the same morning. Here is what is known, what is not, and what it means if you are on a GLP-1 today.

## What is CT-G32? The basics

| Question | Answer |
|---|---|
| Names | CT-G32 (Celltrion), SCO-940 (SCOHIA) |
| Who makes it | Celltrion (Korea), with SCOHIA (Japan) |
| Receptors | GLP-1, GIP, glucagon, amylin |
| Form | Injection; once weekly looks possible based on monkey data |
| Stage | Preclinical (animals only) |
| Next step | IND filing with the US FDA by February 2027 |
| First human dose | Targeted for Q2 2027, if the FDA clears it |
| Approved? | No, anywhere |

The two companies started working together in 2024. SCOHIA handles discovery and early lab work. Celltrion handles human trials, regulators, manufacturing and sales. SCOHIA's April 2026 announcement says it can earn milestone payments plus single-digit royalties on future sales.

## What "quadruple agonist" means

An agonist is a drug that switches a receptor on. Each new generation of obesity drugs has added one more hormone:

| Drug | Receptors | Status (Nov 2026) |
|---|---|---|
| Semaglutide (Wegovy, Ozempic) | GLP-1 | Approved |
| Tirzepatide (Zepbound, Mounjaro) | GLP-1, GIP | Approved |
| Retatrutide | GLP-1, GIP, glucagon | Phase 3 done, filing planned Q1 2027 |
| Amycretin (zenagamtide) | GLP-1, amylin | Phase 3 |
| CT-G32 (SCO-940) | GLP-1, GIP, glucagon, amylin | Animals only |

GLP-1 and GIP mostly calm appetite and help blood sugar. Glucagon is thought to raise energy use and help clear liver fat. Amylin is a fullness hormone your pancreas releases with insulin. Novo Nordisk adds amylin through [CagriSema](/blog/cagrisema/) and [amycretin](/blog/amycretin-zenagamtide/). Lilly is pairing an amylin drug with tirzepatide in [EloraTZP](/blog/eloratzp/). Celltrion's bet is that one molecule can do all four jobs.

Celltrion says CT-G32 is the first candidate of its kind. That is the company's own claim, made before any human data, so read "world's first" as a press line rather than a proven fact.

## CT-G32 results: what the animal study showed

Celltrion tested CT-G32 in diet-induced obese rodents. Reports differ on whether they were mice or rats. Compared with retatrutide at the same dose, Celltrion says CT-G32:

- Caused **more weight loss**.
- Led to a **smaller share of lean mass lost**. Lean mass means everything that is not fat, including muscle and bone.
- **Lowered high blood insulin** levels.

Monkey studies showed the drug stays in the blood long enough that weekly dosing could be possible.

What is missing matters just as much. The press release gave **no percentages, no doses and no side effect data**. Korea Biomedical Review notes the detailed numbers were shown only at the conference. Earlier, Celltrion had said modeling suggested up to 25% weight loss, but that was a projection, not a result.

Animal results are a weak guide. Many drugs that look great in rodents fail or shrink in people. A smaller share of lean mass lost in a rat is a nice signal, not proof that the drug protects human muscle.

## CT-G32 vs retatrutide

| | CT-G32 | Retatrutide |
|---|---|---|
| Company | Celltrion and SCOHIA | Eli Lilly |
| Receptors | 4 | 3 |
| Tested in humans | No | Yes, thousands of people |
| Best human result | None yet | 28.3% at 80 weeks (TRIUMPH-1, 12 mg) |
| Side effect data | None | Nausea, diarrhea, vomiting, dysesthesia |
| Earliest approval | Many years away | Filing planned Q1 2027 |

Retatrutide is roughly a decade ahead. Our [retatrutide guide](/blog/retatrutide-guide/) covers its trials, and our [UBT251 guide](/blog/ubt251/) covers Novo Nordisk's own three-receptor rival. For a simpler GLP-1-only shot that is much further along, see our [bofanglutide guide](/blog/bofanglutide/), which covers Gan & Lee's every-two-week and once-monthly results.

## When will CT-G32 be available?

Here is the public timeline:

- **2024:** Celltrion and SCOHIA start working together.
- **April 2026:** SCOHIA announces SCO-940/CT-G32.
- **May 2026:** Safety testing starts in 252 rats and 48 monkeys.
- **November 4, 2026:** First efficacy data at TIDES Europe.
- **By February 2027:** IND filing with the FDA (target).
- **Q2 2027:** First person dosed (target).

A new drug usually needs Phase 1, 2 and 3 trials after that, which usually takes many years. There is no price and no way to get CT-G32 legally outside a future clinical trial. Anything sold online under this name is not a real medicine.

## Bigger weight loss makes muscle matter more

Every drug that causes fast weight loss also removes some lean tissue. Celltrion is pitching lower lean loss because it is the top worry with these drugs. You do not have to wait for a fourth receptor to act on that worry. The steps that protect muscle work on any GLP-1:

- **Eat enough protein.** Many experts suggest about 1.2 to 1.6 grams per kilogram of goal body weight a day. Ask your care team what fits you.
- **Lift two to three times a week.** Short strength sessions are enough to signal your body to keep muscle.
- **Track more than the scale.** Waist size, strength and photos show whether you are losing fat or muscle.

[Sharpy](https://apps.apple.com/us/app/glp-diet-app-sharpy/id6762084138) turns those three steps into one protein target, one 20-minute workout and one Shape Score a day, so you can see if your weight loss is fat or muscle. For the science behind it, read our [Ozempic weight loss guide](/blog/ozempic-weight-loss-guide/).

## The bottom line

CT-G32 is an early, interesting idea: one weekly shot that hits GLP-1, GIP, glucagon and amylin. The first animal data beat retatrutide at the same dose, but no human has taken it, and key numbers are not public. Human trials may start in 2027. If you are on Wegovy, Zepbound or another GLP-1 now, the best thing you can do is protect your muscle with protein and strength work, and [Sharpy](https://apps.apple.com/us/app/glp-diet-app-sharpy/id6762084138) makes that a daily habit.

## Sources

- [Celltrion Unveils Preclinical Data on Quadruple-Action Obesity Drug, Seoul Economic Daily, November 4, 2026](https://en.sedaily.com/finance/2026/11/04/celltrion-unveils-preclinical-data-on-quadruple-action)
- [Celltrion's 4-hormone obesity drug beats Lilly's retatrutide on weight loss in rat study, Korea Biomedical Review, November 4, 2026](https://www.koreabiomed.com/news/articleView.html?idxno=33721)
- [SCOHIA announces generation of novel quadruple agonist SCO-940/CT-G32, SCOHIA, April 3, 2026](https://www.scohia.com/eng/sys/news/250403sco940generation_en/)
- [Celltrion nears end of preclinical trials for quadruple-action obesity drug, Seoul Economic Daily, May 29, 2026](https://en.sedaily.com/finance/2026/05/29/celltrion-nears-end-of-preclinical-trials-for-world-first)
- [Celltrion joins obesity drug race with oral, injectable pipeline, The Korea Herald, February 24, 2026](https://www.koreaherald.com/article/10681298)
- [Retatrutide TRIUMPH-1 and TRIUMPH-2 results, Pharmaceutical Executive, July 23, 2026](https://www.pharmexec.com/view/retatrutide-delivers-22-weight-loss-two-phase-iii-trials)


## Frequently asked questions

**Q: What is CT-G32?**

A: CT-G32 is an investigational obesity drug candidate from Celltrion, developed with the Japanese company SCOHIA, which calls it SCO-940. It is one molecule designed to activate four receptors: GLP-1, GIP, glucagon and amylin. It is meant to be an injection, and Celltrion says early animal data suggest once-weekly dosing could work. It is not approved and has not been given to people.

**Q: What is a quadruple agonist GLP-1?**

A: A quadruple agonist is a single drug that switches on four different hormone receptors. Semaglutide (Wegovy) acts on one, GLP-1. Tirzepatide (Zepbound) acts on two, GLP-1 and GIP. Retatrutide acts on three, adding glucagon. CT-G32 adds a fourth, amylin, a fullness hormone made by the pancreas.

**Q: Is CT-G32 better than retatrutide?**

A: Nobody knows yet. Celltrion says CT-G32 caused more weight loss than retatrutide at the same dose in diet-induced obese rodents, but it did not release the percentages in its press release. Animal results often do not carry over to people. Retatrutide has finished large Phase 3 trials in humans, with 28.3% average weight loss on the top dose at 80 weeks in TRIUMPH-1.

**Q: Does CT-G32 prevent muscle loss?**

A: That has not been shown. Celltrion said the share of lean mass lost was smaller than with the comparator drug in animals. Lean mass includes muscle, bone, water and organs, so this does not prove the drug protects muscle, and it says nothing about people.

**Q: When will CT-G32 be available?**

A: Not for years. Celltrion plans to file an Investigational New Drug application with the US FDA by February 2027 and hopes to dose the first patient in the second quarter of 2027. After that it would still need Phase 1, 2 and 3 trials before any approval.

**Q: What are the side effects of CT-G32?**

A: There is no human safety data. No side effects have been reported because the drug has only been tested in animals. Drugs that act on GLP-1 and amylin usually cause nausea and other stomach effects, but that is a general pattern, not a CT-G32 finding.